# A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Source: https://onco.cc/trials/nct04817007/  
OnCo record `nct04817007` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ruxolitinib and Fedratinib in myeloproliferative neoplasms, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) is a phase 1/2 interventional study registered as NCT04817007 by Bristol-Myers Squibb, with 216 participants enrolled, started 2021-03-22 and due to reach its primary completion in 2028-08-31. Interventions recorded: BMS-986158, Ruxolitinib and Fedratinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04817007
- Phase: 1/2
- Setting: A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination With Either Ruxolitinib or Fedratinib in Participants With DIPSS-Intermediate or High Risk Myelofibrosis
- Sponsor: Bristol-Myers Squibb
- Enrolled: 216

## Sources

- ClinicalTrials.gov NCT04817007: https://clinicaltrials.gov/study/NCT04817007

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Fedratinib](https://onco.cc/drugs/fedratinib/), [Ruxolitinib](https://onco.cc/drugs/ruxolitinib/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct04817007.json